At the news
? MIXEDIMPACT 7/10 PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET
Vera Therapeutics reported Q2 2026 net loss of $109.5M (-$1.52 EPS), wider than the $76.5M loss in Q2 2025 and a miss vs consensus (-$1.69 EPS implied by the Q1 context miss pattern vs -$1.59 consensus). The key positive is the FDA accelerated approval of TRUTAKNA and its early commercial launch in IgAN, offset by a cash burn of $206.8M in H1 2026 and no revenue yet.
- FDA accelerated approval of TRUTAKNA (atacicept-vymj) for IgAN, first BAFF/APRIL inhibitor approved
- U.S. commercial launch underway; early reception described as encouraging
- Q2 2026 net loss of $109.5M vs $76.5M in Q2 2025; operating expenses $112.5M vs $80.1M
- Net cash used in operating activities H1 2026: $206.8M vs $109.2M in H1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access